1. Generics Bulletin
  2. >>Business
  3. >>Deals

Dr Reddy’s Teams Up With Kainomyx For Anti-Malarial Drug Development

Dr Reddy’s Subsidiary Aurigene Will Handle Drug Chemistry

 
• By Adam Zamecnik

Marking another step in Dr Reddy’s diverse corporate strategy, the company has signed a memorandum of understanding with Kainomyx for the development and commercialization of anti-malarials in multiple markets.

Hands holding paper No mosquito, bite for World malaria day with Stop mosquito sign for prevention of virus,dengue, chikungunya, Zika, Mayaro, Malaria, flavi ep
• Source: Shutterstock/ Justinboat.29

Dr. Reddy's Laboratories and its subsidiary CRDMO Aurigene Pharmaceutical Services have signed a non-binding memorandum of understanding with the US-based firm Kainomyx for the development and commercialization of anti-malarial drugs in the US, Europe and low and middle-income countries.

Under terms of the deal, Kainomyx will handle both the technical strategy and tasks linked to the drug discovery and clinical phases

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.